CD8A and sarcoma: In a different study, the combination of bempegaldesleukin, a PEGylated recombinant human interleukin-2 designed to induce activation and proliferation of CD8 T-cells and NK cells, with nivolumab (anti-PD1) did not improve the efficacy in sarcomas, including a small cohort of SyS (ClinicalTrials.gov Identifier: NCT03282344) [56].